Curaleaf Holdings, Inc.

CURA.TOTSXHealthcare● Active

$16.21

+$1.00(+6.57%)

Market Cap$3.8B

P/E Ratio—

52W High$16.92

52W Low$0.99

Avg Volume826K

Open$15.00

Beta1.64

Free Cash Flow Financials Revenue

Curaleaf Holdings, Inc. (CURA.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CURA.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

CURA.TO · FCF · TTM · margin & CAGR

Free cash flow was $75.8M for FY2025 (fiscal year ending 2025-12-31), up 17.7% year-over-year The FCF margin was 5.9%.

FY2025 Free Cash Flow$75.8M▲ +17.7% YoY

Trailing 12M (TTM)$54.5Mtrailing 4 quarters sum

FCF Margin5.9%$75.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CURA.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$140.3M(65M)$75.8M▲ +17.7%5.9%

FY2024$162.6M(98M)$64.4M▲ +1175.9%4.8%

FY2023$75.3M(70M)$5.0M▲ +105.5%0.4%

FY2022$46.4M(138M)−$92.0M▲ +55.3%-6.9%

FY2021−$34.0M(172M)−$205.9M▼ 80.8%-17.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CURA.TO · P/FCF · FCF yield · FCF per share

Curaleaf Holdings, Inc. (CURA.TO) trades at a FCF yield of 1.83% and a price-to-free-cash-flow ratio of 77.2x. FCF per share stands at $0.21, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

1.83%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.21

TTM FCF ÷ Shares Outstanding

Price / FCF

x77.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x71.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CURA.TO · cash flow statement · operating / investing / financing

For FY2025, Curaleaf Holdings, Inc. generated $140.3M in operating cash flow and spent 65M in capital expenditures, yielding $75.8M in free cash flow.

Operating Activities

+$140.3M

Cash from core business operations

2025-12-31

Investing Activities

−$71.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$74.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($140.3M) − |CapEx| (65M) = FCF ($75.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CURA.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Curaleaf Holdings, Inc.YOU

CURA.TO

$75.8M+17.7%5.9%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Curaleaf Holdings, Inc. (CURA.TO) reported free cash flow of $75.8M for FY2025 (fiscal year ending 2025-12-31), up 17.7% year-over-year. The FCF margin was 5.9%.

Based on available data, Curaleaf Holdings, Inc. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $75.8M in FY2025.

Curaleaf Holdings, Inc.'s FCF yield is 1.83% and price-to-FCF ratio is 77.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CURA.TO free cash flow · 8 questions

Curaleaf Holdings, Inc. free cash flow was $75.8M for FY2025, up 17.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $54.5M.

CURA.TO free cash flowCURA.TO FCFCURA.TO FCF 2025CURA.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Curaleaf Holdings, Inc. · Curaleaf Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026